arrow
J

Jimin Wu

Nanjing Forestry University
H指数:39
被引数:5,087

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study

帕博利珠单抗联合化疗与化疗对比治疗晚期食管癌:KEYNOTE-590随机III期研究的5年扩展随访

2025-11-180
OAAI
Phase I/II open-label, umbrella platform designed study of investigational agents with or without pembrolizumab and/or chemotherapy in patients with advanced esophageal cancer previously treated with a PD-(L)1 inhibitor: KEYMAKER-U06 substudy 06B

I期/II期开放标签、伞式平台设计研究,评估在既往接受过PD-(L)1抑制剂治疗的晚期食管癌患者中,研究药物联合或不联合帕博利珠单抗和/或化疗的疗效:KEYMAKER-U06研究的06B亚研究。

2024-12-010
PRE
Levorphanol as a Second Line Opioid in Cancer Patients Presenting to an Outpatient Supportive Care Center: An Open-label Study
2023-06-013
PRE
Open vs minimally invasive radical trachelectomy in early-stage cervical cancer: International Radical Trachelectomy Assessment Study
2022-01-0140
OAAI
Oncology patients' perception of physicians who use an integrated electronic health record (EHR) during clinic visits: PRIME-EHR double-blind, randomized controlled trial

肿瘤科患者对临床就诊期间使用综合电子健康记录 (EHR) 的医生的看法: PRIME-EHR双盲随机对照试验

CANCER
IF5.1
2021-07-152
OAAI
Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer

乳腺癌和前列腺癌患者化疗前、期间和化疗后药物 (包括草药和补充剂) 潜在相互作用的患病率

CANCER
IF5.1
2021-02-0128
OAAI
A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma
2020-03-1331
OAAI
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages

帕博利珠单抗在复发性胶质母细胞瘤患者中的机会之窗临床试验揭示了免疫抑制性巨噬细胞的优势

2019-11-22114
OAAI